On Wednesday, Pharmaceutical Giant Pfizer Agreed to Buy Baxter International's Vaccines Unit Worth $635 Million

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015 November 17, 2014 Pfizer Inc. announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to …

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer vaccines, and these are the …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

Potential Lung Cancer Vaccine Shows Renewed Promise

March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an …

Interview: Combination therapies for cancer treatment

Recently, Dr Marc Mansour, Chief Operating Officer and Director at Immunovaccine Inc sat down with Vaccine Nation to talk about cancer vaccines and particularly the need for combination therapies: What’s the need for combination therapies and how much of an improvement can we see compared to individual vaccines? I think that for a number of reasons there’s growing recognition now in the …

Glaxo’s MAGE-A3 melanoma cancer vaccine disappoints in late-stage trial

GlaxoSmithKline's MAGE-A3 experimental cancer vaccine was known to be risky, but if pivotal Phase III trial data impressed then a potential blockbuster was on the cards. However, the news just in on the MAGE-A3 immunotherapy will disappoint GSK and melanoma patients alike. The cancer vaccine failed to significantly extend disease-free survival in melanoma patients in a late-phase clinical trial, and …

Immunization Strategies for the Developing World

The second morning session of Day One at the World Vaccine Congress USA 2013 started with Dr John Boslego, Global Program Leader, Vaccine Development at PATH, delivering a talk entitled ‘Driving the development of much needed vaccines for the developing world'. He spoke about the work of PATH, and introduced the 3 pillars of PATH – namely 1) Advancing technologies, …

Interview with George Adams from EMD Millipore

George Adams, Vaccine Program Manager, EMD Millipore tells us why he sponsors the World Vaccine Congress. EMD Millipore (known as Merck Millipore outside of the U.S. and Canada) is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and …

Download – Investing in Asia: Enabling vaccine industry success

Interested in entering Asia’s vaccine market? Learn how to succeed from Dr. Matthias Bucerius, Head of Sales Asia, Pharm Chemicals Soltuions, Merck Millipore, Germany. Dr. Bucerius joined the in-house Consulting Department of Merck KGaA in 2004. During his time working out of Darmstadt, he supported projects for Merck’s Chemicals and Pharma Business Sectors and Central Functions. In 2007, Dr. Bucerius …